In this way, the use of IFN therapy in COVID-19 needs precision medicine approaches, considering the favorable antiviral activity of IFN together with other direct antiviral therapies in early/mild infection and enhancement of harmful cytokine storm events in severe/late infections [126]. The gene discussed is IFNA1; the disease is infection.